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Getting to the Nucleus of Mitochondrial Disorders: Identification of
Respiratory Chain–Enzyme Genes Causing Leigh Syndrome
Hans-Henrik M. Dahl
The Murdoch Institute, Royal Children’s Hospital, Melbourne
In 1951, Denis Leigh first described a striking neuro-
pathology that occured in a child who died of a neu-
rodegenerative disease (Leigh 1951). The paper focused
on the patient’s distinct neuropathological abnormali-
ties, which we now associate with Leigh disease, or Leigh
syndrome (MIM 256000). Definite diagnosis of this neu-
rodegenerative disorder still depends on the identifica-
tion, either in postmortem samples or by use of neu-
roimaging techniques, of the characteristic neuropa-
thology of focal, bilaterally symmetrical spongiform le-
sions, especially in the thalamus and brain stem regions.
This neuropathology is associated with demyelination,
vascular proliferation, and gliosis. Onset is usually
within the 1st year of life but can be later, and the clinical
features and course of the disease vary among patients.
Symptoms often include motor and/or intellectual re-
tardation, abnormal breathing rhythm, nystagmus, op-
thalmoparesis, optic atrophy, ataxia, and dystonia.
Death is usually within 2 years of onset, although slower
progression is not unusual.
It was originally suggested that the biochemical defect
in Leigh syndrome is a block in thiamine metabolism,
but it is now clear that the defect is a result of severe
deficiency in mitochondrial ATP production. Leigh syn-
drome is one of the most commonly recognized disorders
of mitochondrial energy production and can be regarded
as one part of the spectrum of these disorders. For ex-
ample, some mutations in mtDNA, when present in high
proportions in affected tissues, will cause Leigh syn-
drome, whereas lower levels of mutant mtDNA will
cause milder phenotypes. In a similar manner, severe
mutations in some nuclear genes appear to result in
Leigh syndrome, but functionally less-severe mutations
in the same genes give rise to different clinical presen-
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tations. Because of this and because of the difficulty of
establishing a definite clinical diagnosis, it could be ar-
gued that, for many patients, a more appropriate term
for their condition would be “Leigh-like syndrome” or
“mitochondrial encephalopathy.”
Although initial observations suggested autosomal re-
cessive inheritance, it soon became clear that inheritance
could also be autosomal dominant, X-linked, or mater-
nal, which indicated that causative genes exist in both
the nuclear and the mitochondrial genome. Genetic het-
erogeneity has been confirmed by identification of func-
tional or molecular defects in several enzyme systems
involved in mitochondrial energy production, including
the pyruvate dehydrogenase complex (PDHC), respira-
tory chain complexes I, II, and IV (cytochrome c oxidase
[COX]), and the mitochondrial-encoded ATPase6 sub-
unit (DiMauro and De Vivo 1996). Because of difficul-
ties associated with the measurement of the activity of
these enzyme complexes, especially complex I, there is
some variation in the estimate of the relative incidence
of the various causes. We published a study of 67 pa-
tients with Leigh or Leigh-like syndrome (Rahman et al.
1996) and were able to determine the cause in approx-
imately two-thirds of the cases (table 1). These frequen-
cies generally agree with those reported by Morris et al.
(1996).
A number of mutations causing Leigh syndrome have
been identified in mtDNA. Analysis of these mutations
illustrates the complex genotype-phenotype correlation
in mtDNA disorders. The TrG and TrC mutations at
nucleotide 8993 in the ATPase6 gene are the most com-
mon. The T8993G mutation initially was associated
with neuropathy, ataxia, and retinitis pigmentosa but
later was found in patients with Leigh syndrome (Tatuch
et al. 1992). As with other mtDNA mutations, the clin-
ical presentations can vary significantly among affected
individuals, most likely as a result of variations in the
proportions of mutant DNA (heteroplasmy) in the dif-
ferent tissues. One would expect the Leigh syndrome
patients to have a high proportion of T8993Gmutations
in affected tissues. Leigh syndrome patients who carry
the ArG mutation at nucleotide 8344 in the tRNALys
gene (a mutation that is ordinarily associated with
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Table 1
Causes of Leigh or of Leigh-like Syndrome
Defect
Frequencya
(%)
Component(s) of
Affected Genes
mtDNA 18 ATPase6 (nt 8993, nt 9176), tRNALys
(nt 8344), mtDNA deletions
PDHC 10 E1a subunit
Complex I 19 NDUFS8
COX 14 SURF-1
Other 39 Flavoprotein subunit of complex II
mtDNA depletion?
a Rahman et al. 1996.
MERRF [myoclonic epilepsy with ragged red fibers] syn-
drome), the TrC mutation at nucleotide 9176 in the
ATPase6 gene, or mtDNA deletions are also presumed
to carry high mutant loads in specific tissues. mtDNA
depletion, which is likely to be caused by a nuclear-gene
defect, has also been associated with Leigh syndrome
(Morris et al. 1996).
Cloning of the subunits of the PDHC enabled us to
search for mutations in patients with Leigh syndrome
resulting from deficiency of PDHC activity. In the ma-
jority of these patients, the defect occurs in the catalytic
subunit, E1a. The X linkage of the PDHC E1a gene
partially explains the predominance of males with this
disorder. However, females with Leigh syndrome and a
mutation in PDHC E1a have also been identified.
Whether a male develops Leigh syndrome will largely
depend on the functional severity of the E1a mutation.
In females, the clinical presentation will also depend on
the X chromosome–inactivation pattern in different tis-
sues, especially in the brain (Dahl 1995). A mutation
has also been found in the flavoprotein subunit of com-
plex II in two siblings with Leigh syndrome (Bourgeron
et al. 1995).
Mutations in mtDNA or in PDHC subunits appear to
account for approximately one-third of Leigh syndrome
patients. If, however, analysis of defects in these genes
has been relatively straightforward and productive, then
the molecular analysis of the other common causes of
Leigh syndrome has been slow and frustrating. This issue
of the Journal includes two articles that identify muta-
tions in nuclear genes leading to Leigh syndrome. Tiranti
et al. (1998 [in this issue]) have identified defects in the
Surfeit-1 (SURF-1) protein that result in COX deficiency,
and Loeffen et al. (1998 [in this issue]) have found mu-
tations in the NADH:ubiquinone oxidoreductase 23-kD
subunit (NDUFS8) protein that cause complex I defi-
ciency. Two different approaches were used to find the
causative genes.
The success of a direct approach is demonstrated by
Loeffen et al. (1998). An increasing number of nuclear
genes encoding complex I subunits are being character-
ized, and a logical response is to search for mutations
in these genes. Often, bacteria, yeast, or bovine complex
I subunit genes are used to identify the human homo-
logues. When Loeffen et al. analyzed patients with com-
plex I deficiency for mutations in the NDUFS8 gene,
they found that one of their patients, a child who died
from Leigh syndrome, had amino acid substitutions in
both alleles. This does not definitively prove that these
changes are the causative mutations and that the
NDUFS8 gene is the defective gene, but the type and
location of the amino acid substitution supports the au-
thors’ conclusions. NDUFS8 is a highly conserved and
important structural complex I subunit (Chevallet et al.
1997). It is, therefore, conceivable that changes in
NDUFS8 can severely affect complex I function and
cause Leigh syndrome.
In their search for candidate genes, Loeffen et al.
(1998) took advantage of data generated by analysis of
respiratory chain–enzyme defects in other organisms, es-
pecially in yeast. Such information also proved very use-
ful for Tiranti et al. (1998). Better comprehension of
complex I deficiency and of Leigh syndrome may have
to wait until most or all of the 135 nuclear-encoded
subunits have been characterized. Even then, it is un-
likely that all disease-causing mutations will be in the
genes for these structural subunits. The study of COX
deficiency in Leigh syndrome (LD[COX]) suggests that the
picture is more complex than anticipated. COX consists
of 10 nuclear-encoded and 3 mtDNA-encoded structural
subunits. Two tissue-specific isoforms are found for 2 of
the nuclear-encoded subunits. The nucleotide sequences
of all 15 genes are known. Pedigree analysis (Van Coster
et al. 1991) and cybrid (Tiranti et al. 1995) and com-
plementation studies (Munaro et al. 1997) have so far
shown that LD(COX) is inherited as an autosomal reces-
sive condition. The 12 nuclear-encoded COX genes are
obvious candidate genes for LD (COX). Extensive inves-
tigations in several laboratories, however, have failed to
find defects in any of these genes (Adams et al. 1997;
H.-H. M. Dahl, D. R. Thorburn, and L. Peters, unpub-
lished data; M. Hirano, personal communication). This
failure would indicate that the defects are in genes that
are involved in the processing, modification, mitochon-
drial import, or assembly of the COX complex. This
perhaps is not surprising, since genetic analysis of yeast
mutants has revealed that an unexpectedly large number
of genes (136) are required for generation of functional
COX (McEwen et al. 1986; Tzagoloff and Dieckmann
1990).
How can we map and identify the human genes caus-
ing mitochondrial dysfunction, such as LD(COX), when
analysis of the obvious candidate genes is unsuccessful?
Tiranti et al. (1998) show that a locus for LD(COX) is
located on chromosome 9q34-qter. Identification of this
locus has been achieved by use of a novel and ingenious
approach (fig. 1). mtDNA was eliminated from a panel
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Figure 1 Schematic outline of complementation and selection
strategy (Tiranti et al. 1998). Human chromosomes are shown as thick
lines, mouse chromosomes and are shown as thin lines. Mitochondria
and mtDNA are also indicated. The fused cell line will be COXpositive
if the mutation is complemented by the wild-type gene on the human
chromosome(s) supplied by the human/rodent cell line.
of rodent/human cell hybrids expressing a selectable
marker (e.g., G418 resistance) and containing one or
more human chromosomes. These were fused with a
patient cell line that had been made resistant to puro-
mycin. Fused cells were isolated in medium without uri-
dine but containing G418 and puromycin and were an-
alyzed by use of COX immunohistochemistry and
enzyme analyses. When the rodent/human cell supplied
a complementing human chromosome (in this case chro-
mosome 9), the fused cells became COX positive. The
success of this approach is dependent on the rodent
background not interfering with the COX phenotype.
This was shown to be the case in the LD(COX) comple-
mentation group studied, and it could be a common
feature in other mitochondrial disorders caused by mu-
tations in nuclear genes.
Munaro et al. (1997) previously had demonstrated
that all their LD(COX) patients belonged to one comple-
mentation group. This allowed them to perform linkage
analysis of 10 families with chromosome 9 markers and
to map the disease locus to a 9-cM region betweenmark-
ers D9S1847–D9S1826. This region does not code for
any COX subunit genes, but analysis of candidate genes
showed that the probands in all 10 LD(COX) families had
mutations in the gene coding for SURF-1. SURF-1 is a
mitochondrial protein of unknown function, which af-
fects respiratory chain and, especially, COX function. It
is surprising that, although the LD(COX) patients belong
to one complementation group, there is no suggestion
of a founder mutation. Instead, nine different mutations
were characterized. Further studies have shown that not
all LD(COX) patients belong to the same complementa-
tion group (Brown and Brown 1996; Tiranti et al. 1998;
D. R. Thorburn and H.-H. M. Dahl, unpublished data).
These results indicate that LD(COX) is genetically hetero-
geneous and that more mutations and chromosomal loci
will be identified. Tiranti et al. have devised a very pow-
erful way of mapping other nuclear genes involved in
mitochondrial dysfunction, not just those that cause
LD(COX).
There are several reasons why the articles by Tiranti
et al. and Loeffen et al. are exciting. They outline ways
to identify nuclear-encoded mitochondrial genes that
will provide new information on the pathways that lead
to successful import, assembly, and function of respi-
ratory chain enzymes. Furthermore, the genes for
LD(COX) are likely to belong to a group of nuclear genes
controlling mitochondrial function, similar to the re-
cently identified genes for Friedreich ataxia and spastic
paraplegia (Campuzano et al. 1996; Casari et al. 1998).
The use of these elegant approaches is likely to be a
rewarding exercise. These approaches eventually will in-
crease our understanding of the complex interactions
between the mitochondrial and nuclear genomes and
will shed light on the molecular causes of this group of
relatively common but genetically and clinically complex
and poorly understood neurodegenerative disorders.
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